KR102553382B1 - 세포에서 lpa의 발현을 저해하기 위한 핵산 - Google Patents

세포에서 lpa의 발현을 저해하기 위한 핵산 Download PDF

Info

Publication number
KR102553382B1
KR102553382B1 KR1020207016884A KR20207016884A KR102553382B1 KR 102553382 B1 KR102553382 B1 KR 102553382B1 KR 1020207016884 A KR1020207016884 A KR 1020207016884A KR 20207016884 A KR20207016884 A KR 20207016884A KR 102553382 B1 KR102553382 B1 KR 102553382B1
Authority
KR
South Korea
Prior art keywords
strand
nucleotides
nucleic acid
modified
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207016884A
Other languages
English (en)
Korean (ko)
Other versions
KR20200088392A (ko
Inventor
쥐빌레 다메스
슈테펜 슈베르트
슈테판 텐바움
크리스티안 프라우엔도르프
루카스 베트게
주디스 하웁트만
아드리엔 바인게르트너
데이비드 앤서니 라이더
Original Assignee
사일런스 테라퓨틱스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17201449.0A external-priority patent/EP3483270A1/en
Application filed by 사일런스 테라퓨틱스 게엠베하 filed Critical 사일런스 테라퓨틱스 게엠베하
Publication of KR20200088392A publication Critical patent/KR20200088392A/ko
Application granted granted Critical
Publication of KR102553382B1 publication Critical patent/KR102553382B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207016884A 2017-11-13 2018-11-13 세포에서 lpa의 발현을 저해하기 위한 핵산 Active KR102553382B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17201449.0A EP3483270A1 (en) 2017-11-13 2017-11-13 Products and compositions
EP17201449.0 2017-11-13
EP18179175.7 2018-06-21
EP18179175.7A EP3483271A3 (en) 2017-11-13 2018-06-21 Products and compositions
GB201815915 2018-09-28
GB1815915.2 2018-09-28
PCT/EP2018/081106 WO2019092283A1 (en) 2017-11-13 2018-11-13 Nucleic acids for inhibiting expression of lpa in a cell

Publications (2)

Publication Number Publication Date
KR20200088392A KR20200088392A (ko) 2020-07-22
KR102553382B1 true KR102553382B1 (ko) 2023-07-07

Family

ID=66439085

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207016884A Active KR102553382B1 (ko) 2017-11-13 2018-11-13 세포에서 lpa의 발현을 저해하기 위한 핵산

Country Status (22)

Country Link
US (3) US11319537B2 (https=)
EP (2) EP3710586B1 (https=)
JP (1) JP7245254B2 (https=)
KR (1) KR102553382B1 (https=)
CN (2) CN111465694A (https=)
AU (1) AU2018363840B2 (https=)
BR (1) BR112020009152A2 (https=)
CA (1) CA3081905C (https=)
DK (1) DK3710586T3 (https=)
ES (1) ES2938193T3 (https=)
FI (1) FI3710586T3 (https=)
HR (1) HRP20230127T1 (https=)
HU (1) HUE061265T2 (https=)
IL (1) IL274503B2 (https=)
LT (1) LT3710586T (https=)
MX (1) MX2020004897A (https=)
PL (1) PL3710586T3 (https=)
RS (1) RS63955B1 (https=)
SG (1) SG11202003230UA (https=)
SI (1) SI3710586T1 (https=)
WO (1) WO2019092283A1 (https=)
ZA (1) ZA202003371B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065423T2 (hu) 2015-12-16 2024-05-28 6K Inc Eljárás szferoidális dehidrogénezett titánötvözet részecskék elõállítására
US10987735B2 (en) 2015-12-16 2021-04-27 6K Inc. Spheroidal titanium metallic powders with custom microstructures
JP7155239B2 (ja) * 2017-04-05 2022-10-18 サイレンス・セラピューティクス・ゲーエムベーハー 産物及び組成物
MX2020004897A (es) 2017-11-13 2020-10-05 Silence Therapeutics Gmbh Acidos nucleicos para inhibir la expresion de lpa en una celula.
WO2019143621A1 (en) 2018-01-16 2019-07-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting aldh2 expression
AU2019290663B2 (en) 2018-06-19 2023-05-04 6K Inc. Process for producing spheroidized powder from feedstock materials
BR112021009213A2 (pt) * 2018-11-13 2021-08-10 Silence Therapeutics Gmbh ácidos nucleicos para inibição da expressão de lpa em uma célula
CA3135402A1 (en) * 2019-04-04 2020-10-08 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression in the central nervous system
CA3134573A1 (en) 2019-04-30 2020-11-05 Sunil Bhalchandra BADWE Mechanically alloyed powder feedstock
WO2021118762A1 (en) 2019-11-18 2021-06-17 6K Inc. Unique feedstocks for spherical powders and methods of manufacturing
US20230078200A1 (en) * 2019-12-09 2023-03-16 Amgen Inc. RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
AU2021297476A1 (en) 2020-06-25 2022-12-15 6K Inc. Microcomposite alloy structure
KR102812602B1 (ko) 2020-08-05 2025-05-28 다이서나 파마수이티컬, 인크. Lpa 발현을 저해하기 위한 조성물 및 방법
AU2021349358A1 (en) 2020-09-24 2023-02-09 6K Inc. Systems, devices, and methods for starting plasma
US20240035029A1 (en) * 2020-10-16 2024-02-01 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
EP4237174A1 (en) 2020-10-30 2023-09-06 6K Inc. Systems and methods for synthesis of spheroidized metal powders
WO2022098841A1 (en) * 2020-11-05 2022-05-12 Amgen Inc. METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
US20250304966A1 (en) 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
EP4275239A4 (en) 2021-01-11 2024-12-18 6K Inc. METHODS AND SYSTEMS FOR RECLAIMING LI-ION CATHODE MATERIALS USING MICROWAVE PLASMA TREATMENT
AU2022246797A1 (en) 2021-03-31 2023-10-05 6K Inc. Systems and methods for additive manufacturing of metal nitride ceramics
WO2023041508A2 (en) 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease
IL312811A (en) 2021-11-16 2024-07-01 Shanghai Argo Biopharmaceutical Co Ltd Composition and method for inhibiting angiotensinogen (agt) protein expression
IL312743A (en) * 2021-11-18 2024-07-01 Novartis Ag Compounds targeting PMP22 for the treatment of Charcot-Marie-Shen disease
PE20241340A1 (es) 2021-11-24 2024-07-03 Adarx Pharmaceuticals Inc Composiciones moduladoras de complemento del factor b y metodos de uso de estas
TW202345865A (zh) * 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
EP4522742A2 (en) 2022-05-13 2025-03-19 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2023229928A1 (en) 2022-05-23 2023-11-30 6K Inc. Microwave plasma apparatus and methods for processing materials using an interior liner
US12040162B2 (en) 2022-06-09 2024-07-16 6K Inc. Plasma apparatus and methods for processing feed material utilizing an upstream swirl module and composite gas flows
WO2024006999A2 (en) 2022-06-30 2024-01-04 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024044498A1 (en) 2022-08-25 2024-02-29 6K Inc. Plasma apparatus and methods for processing feed material utilizing a powder ingress preventor (pip)
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
US12195338B2 (en) 2022-12-15 2025-01-14 6K Inc. Systems, methods, and device for pyrolysis of methane in a microwave plasma for hydrogen and structured carbon powder production
IL321855A (en) * 2023-01-13 2025-08-01 Lilly Co Eli Pharmaceutical preparations containing therapeutic oligonucleotides and dosage regimens using the same
WO2024238385A2 (en) 2023-05-12 2024-11-21 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024240056A1 (zh) 2023-05-19 2024-11-28 深圳信立泰药业股份有限公司 一种磺酰胺类化合物及其制备方法和医药用途
CN119563025A (zh) 2023-07-04 2025-03-04 石药集团中奇制药技术（石家庄）有限公司 一种抑制LP(a)基因表达的dsRNA分子及其应用
WO2025082058A1 (zh) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 一种抑制LPA基因表达的dsRNA及其用途
WO2025103391A1 (zh) * 2023-11-15 2025-05-22 北京加科瑞康医药科技有限公司 用于抑制lpa的基因表达的sirna，含其的组合物及其用途
CN120098993A (zh) * 2023-12-05 2025-06-06 广东东阳光药业股份有限公司 一种新型的双链siRNA、其缀合物及其用途
WO2026008063A1 (en) * 2024-07-05 2026-01-08 Geneditbio Limited Methods and compositions for lpa gene editing and therapy using crispr system
WO2026046152A1 (zh) * 2024-08-26 2026-03-05 倍臻生物技术（苏州）有限公司 修饰的双链核糖核酸及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016149020A1 (en) 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
US20110110886A1 (en) * 2008-06-13 2011-05-12 Yale University Small molecule inhibitors of autotaxin and methods of use
CN108148838A (zh) * 2012-05-22 2018-06-12 奥利克斯医药有限公司 具有细胞内穿透能力的诱导rna干扰的核酸分子及用途
JOP20160211B1 (ar) * 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
EP3228326A1 (en) * 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleic acid linked to a trivalent glycoconjugate
JP7155239B2 (ja) 2017-04-05 2022-10-18 サイレンス・セラピューティクス・ゲーエムベーハー 産物及び組成物
CA3118327A1 (en) 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of aldh2 in a cell
MX2020004897A (es) 2017-11-13 2020-10-05 Silence Therapeutics Gmbh Acidos nucleicos para inhibir la expresion de lpa en una celula.
BR112021009213A2 (pt) 2018-11-13 2021-08-10 Silence Therapeutics Gmbh ácidos nucleicos para inibição da expressão de lpa em uma célula

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016149020A1 (en) 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Cardiovascular Translational Res.,8권,1호,44-53면(2015.01.)

Also Published As

Publication number Publication date
US20220290144A1 (en) 2022-09-15
US11319537B2 (en) 2022-05-03
EP4219716A2 (en) 2023-08-02
US12054717B2 (en) 2024-08-06
IL274503A (en) 2020-06-30
CN111465694A (zh) 2020-07-28
KR20200088392A (ko) 2020-07-22
AU2018363840B2 (en) 2022-09-29
US20240327843A1 (en) 2024-10-03
IL274503B2 (en) 2024-10-01
EP3710586B1 (en) 2022-11-23
EP3710586A1 (en) 2020-09-23
HUE061265T2 (hu) 2023-06-28
US20210123048A1 (en) 2021-04-29
RS63955B1 (sr) 2023-02-28
SG11202003230UA (en) 2020-05-28
AU2018363840A1 (en) 2020-04-16
PL3710586T3 (pl) 2023-03-20
MX2020004897A (es) 2020-10-05
FI3710586T3 (fi) 2023-03-02
BR112020009152A2 (pt) 2020-10-27
HRP20230127T1 (hr) 2023-03-31
DK3710586T3 (da) 2023-01-23
CA3081905C (en) 2023-10-03
WO2019092283A1 (en) 2019-05-16
CA3081905A1 (en) 2019-05-16
ES2938193T3 (es) 2023-04-05
CN119120476A (zh) 2024-12-13
LT3710586T (lt) 2023-02-27
JP7245254B2 (ja) 2023-03-23
IL274503B1 (en) 2024-06-01
SI3710586T1 (sl) 2023-03-31
JP2021502120A (ja) 2021-01-28
EP4219716A3 (en) 2024-03-27
ZA202003371B (en) 2023-08-30

Similar Documents

Publication Publication Date Title
KR102553382B1 (ko) 세포에서 lpa의 발현을 저해하기 위한 핵산
KR102553386B1 (ko) 세포에서 lpa의 발현을 저해하기 위한 핵산
EP3483271A2 (en) Products and compositions
EP3549610A1 (en) Nucleic acid conjugates
HK40101613A (en) Nucleic acids for inhibiting expression of lpa in a cell
RU2822093C1 (ru) Нуклеиновые кислоты для ингибирования экспрессии lpa в клетке
HK40048564A (en) Nucleic acids for inhibiting expression of lpa in a cell
MD3880818T2 (ro) Acizi nucleici pentru inhibarea expresei LPA într-o celulă
HK40035007A (en) Nucleic acids for inhibiting expression of lpa in a cell
HK40035007B (en) Nucleic acids for inhibiting expression of lpa in a cell
HK40057735A (en) Nucleic acids for inhibiting expression of lpa in a cell
HK40057735B (en) Nucleic acids for inhibiting expression of lpa in a cell
EA045986B1 (ru) Нуклеиновые кислоты для ингибирования экспрессии lpa в клетке
HK40031790A (en) Nucleic acids for inhibiting expression of lpa in a cell

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200611

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211111

Comment text: Request for Examination of Application

A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20220708

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221123

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230406

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230705

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230705

End annual number: 3

Start annual number: 1

PG1601 Publication of registration